VTRS MEXC RealStocks
Own real VTRS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-15 04:37:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Viatris Inc. (VTRS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $20.84, with a market capitalization of $23.70B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.15 to $21.20. This page covers its latest market performance, valuation, price trends and company information.
$23.70B | |
$20.77 | |
$20.90 | |
$20.39 | |
$20.67 | |
4.78M | |
8.76M | |
-- | |
$21.20 | |
$10.15 | |
-- | |
-- |
Viatris Inc. (VTRS) last closed at $20.84 as of 2026-11-14 00:31:00, up 0.82% ($0.17) from the previous close of $20.67.
During the latest regular trading session, VTRS traded between $20.39 and $20.90, with a volume of 4.78M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Viatris Inc. (VTRS) moved from $18.97 to $20.84, representing a gain of 9.84% ($1.87).
The stock traded between $18.79 and $21.20 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 11.43 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 96.7%
VTRS is currently trading at $20.84, placing it 96.7% of the way from its 52-week low of $10.15 to its 52-week high of $21.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 30,000 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Viatris Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 23, 2026 |
| Payment Date | Dec 16, 2026 |
| Dividend Per Share | $0.12 |
Eligible investors can buy real shares of Viatris Inc. (VTRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to VTRS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between VTRS shares and USD.
VTRS Shares to USD
1.00 VTRS shares = 20.837 USD
Calculations are estimates based on the latest available price and are for reference only.